1. Home
  2. CSTL vs ENVX Comparison

CSTL vs ENVX Comparison

Compare CSTL & ENVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

HOLD

Current Price

$34.49

Market Cap

722.8M

Sector

Health Care

ML Signal

HOLD

Logo Enovix Corporation

ENVX

Enovix Corporation

HOLD

Current Price

$3.00

Market Cap

741.7M

Sector

Miscellaneous

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSTL
ENVX
Founded
2007
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Industrial Machinery/Components
Sector
Health Care
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
722.8M
741.7M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
CSTL
ENVX
Price
$34.49
$3.00
Analyst Decision
Strong Buy
Buy
Analyst Count
6
9
Target Price
$45.50
$13.61
AVG Volume (30 Days)
275.5K
5.3M
Earning Date
05-06-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
40.94
EPS
N/A
N/A
Revenue
$344,229,000.00
$31,821,000.00
Revenue This Year
$2.42
$30.37
Revenue Next Year
$12.69
$238.73
P/E Ratio
N/A
N/A
Revenue Growth
3.66
37.91
52 Week Low
$17.72
$2.85
52 Week High
$44.28
$14.21

Technical Indicators

Market Signals
Indicator
CSTL
ENVX
Relative Strength Index (RSI) 58.21 34.17
Support Level $22.88 N/A
Resistance Level $42.03 $3.55
Average True Range (ATR) 1.44 0.15
MACD 0.01 0.02
Stochastic Oscillator 57.86 19.29

Price Performance

Historical Comparison
CSTL
ENVX

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

About ENVX Enovix Corporation

Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, the United States, Norway, Taiwan, and other regions.

Share on Social Networks: